Raynham, Massachusetts-based DePuy Synthes has agreed to promote the FIBERGRAFT Family of synthetic bone graft materials for Warren, New Jersey-based Prosidyan, Inc.
DePuy Synthes, Prosidyan to Promote FIBERGRAFT
1 min read Premium comments
Secondary#depuysynthes#bonegraft#demineralizedbonematrix
According to DePuy Synthes, these bone graft products are “ultra-porous, easy to use and have been engineered for optimal resorption in clinical use during spine fusion surgery.”
“Prosidyan was founded in 2009 to develop a family of synthetic bioactive bone graft substitutes based on microsized fibers of bioactive glass.”
“Our exclusive agreement with Prosidyan allows us to complete our biomaterials offering through a next generation synthetic solution and provide our customers with a variety of options based on handling preference and needs of their patients,” said Juan-José Gonzalez, president, DePuy Synthes U.S.
Mr. Gonzalez told OTW, “We are excited to work with a company like Prosidyan because they have an innovative product line in the fast-growing biomaterials segment that will allow us to provide new procedural solutions to surgeons who may prefer synthetic bone graft solutions in the treatment of their patients.”
“We will leverage Prosidyan’s longstanding legacy of bringing high quality biomaterials to market with this new broader offering in our portfolio.”
“This promotion agreement gives us the opportunity to have new conversations with new customers around the use of second generation synthetic biomaterials for use in patients undergoing spinal fusion surgery. In a year’s time, we are looking forward to continuing to offer a comprehensive and differentiated biomaterials platform to our surgeon customers as they evaluate options when treating their patients.”
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.